Feature | April 18, 2007 | Cristen C. Bolan

WEB EXCLUSIVE: Quantification Pushes Nuclear Medicine Bedside

2006 - 2007 SNM President Martin P. Sandler, M.D., Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences

“I think quantification is the next big breakthrough in imaging technology,” said the 2006 – 2007 SNM President Martin P. Sandler, M.D., of Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences, in an interview with Imaging Technology News (ITN) on the future of nuclear medicine.
The Society of Nuclear Medicine (SNM) has embarked on a mission to improve healthcare by advancing molecular imaging and therapy, and the SNM 2007 conference program will feature an increased presence of related research. ITN talked to Dr. Sandler about how nuclear medicine will drive personalized medicine in the future.

ITN: How is molecular imaging using imaging technology such as PET, SPECT, MRI and others to develop personalized medicine?

Martin P. Sandler, M.D. (MS): It is the understanding of how cellular function and biological processes of the cell work from the receptor through the cell membrane all the way to the inner functions of the cell. By looking at different receptor sites and different activities of the cell one can develop specific imaging and therapeutic interventions that will be tailored for individuals based on the ability of the receptors to respond to specific probes as well as certain therapeutic interventions.

ITN: How has molecular imaging and nuclear medicine research led to improvements in the diagnosis and treatment of cancer, heart disease and brain disorders?
MS: It has the potential to affect a large variety of diseases, including cardiac disease, and various cancers. We have already seen it with monoclonal antibodies and there is the possibility of that certain brain disorders have the potential to be responsive, as well. It covers a host of different diseases.

ITN: Can you describe what the new program InfoSNM involves and what the objective is?
MS: We have developed a number of live, interactive lifelong learning programs and people can access the educational component and with that is a continuing medical education component that goes along with these. These are live, interactive programs. There is also training of clinicians and technologists with hybrid imaging, which is a key part of the molecular imaging process or where by you have a congruence of different technologies giving different synergistic kinds of information.

ITN: Exactly which hybrids are you referring to?
MS: These hybrids include PET/CT, SPECT/CT and also work being done on PET/MRI.
Simon Cherry, who gave the Henry Wagner lecture at last year’s SNM, showed that scientists have overcome the technical challenges of integrating PET and MRI imaging. There are models now that are being worked on now.
PET/MRI has the advantage s there is of less radiation and MR gives different kinds of information, such as MR spectroscopy’s the ability to overlap MR spectroscopy on a tumor and look at its therapeutic response. All of the different roles of MR versus CT can now be combined potentially with PET, as can CT.

ITN: What are some of the advancements you anticipate will develop in Nuclear Medicine over the next five years?
MS: Besides the translational development of new products and nanoparticle technology, I think that the biggest advancement will be bringing quantitative measurements to the bedside. If you look at cardiac imaging today, we are looking at relative blood flow. We steal blood from parts of the heart that have narrowing of blood vessels and look at compare it to other parts of the heart with normal blood flow. With pharmacological exercises we improve blood flow, we increase blood flow and we look at relative diminishment in blood flow. I think that we are soon going to have technologies, which have high enough contrast count rates and resolution such that we will have the same sensitivity for gamma camera imaging as we do with PET. This will allow us to quantitate absolute blood flow and the ml/min diminish for 100 grams of tissue. I think quantification is the next big breakthrough in imaging technology.

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Overlay Init